Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux vs low molecular weight heparin in conservatively managed acute coronary syndrome
ChiCTR2100049889Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Aug 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux and low molecular weight heparin calcium in acute coronary syndrome (ACS) (2 arms), sponsored by Second Hospital of Shandong University. Primary endpoints: All-cause death within 30 days, Recurrent myocardial infarction and 2 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
fondaparinuxlow molecular weight heparin calcium
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2100049889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049889.